• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LifeVantage Announces Launch of LV360 and Evolve Compensation Plan in Philippines, Taiwan, Hong Kong, and Singapore Markets

    3/3/25 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email

    SALT LAKE CITY, March 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful launch of the Evolve Compensation Plan and other LV360 initiatives into the Philippines, Taiwan, Hong Kong, and Singapore.

    The transition went into effect in these markets on March 1, 2025, after the successful launch of LV360 into Canada, Mexico, and Europe last February, and the launch in the US, Australia, New Zealand and Japan in March 2023.

    "When we launched the LV360 and the Evolve Compensation Plan two years ago, we did so with a clear vision of where the direct sales industry was headed," said Steve Fife, President and CEO of LifeVantage. "That transformation has proven invaluable for our independent Consultants, equipping them for the world we live in today. As we enter this next phase, we're proud to bring this transformation to more international markets and empower Consultants with the tools to help their businesses thrive."

    The Evolve Compensation Plan is designed to reward Consultants generously, providing opportunities for multiple income streams tied to business building and product sales initiatives with a clear path to success. It supports both entrepreneurs focused on sharing and selling products within their networks and those looking to build strong, collaborative teams. With early income bonuses that encourage smart business strategies from day one along with performance and mentorship rewards that recognize leadership and achievement, Consultants are empowered to grow at every stage.

    In today's competitive direct selling landscape, staying ahead requires innovation. With LV360, LifeVantage is not only adapting to evolving consumer and gig economy trends but also creating new opportunities to attract and engage a growing customer base. Its forward-thinking approach ensures Consultants have the tools and incentives to thrive in an ever-changing market.

    "For those seeking flexible income and opportunities, LifeVantage is the perfect place to start," said Fife. "We're committed to staying ahead with cutting-edge products and an unmatched experience for both our Consultants and Customers."

    About LifeVantage Corporation

    LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*

    Public Relations Contact:

    Kristin Price, CerconeBrownCompany

    (609) 672-7332

    [email protected]

    Investor Relations Contact:

    Reed Anderson, ICR

    (646) 277-1260

    [email protected]



    Primary Logo

    Get the next $LFVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewis Darwin bought $20,651 worth of shares (3,955 units at $5.22), increasing direct ownership by 3% to 135,508 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/11/26 4:32:08 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Sales Officer Cunningham Kristen covered exercise/tax liability with 1,926 shares, decreasing direct ownership by 1% to 135,060 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    1/5/26 6:00:18 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Neufeld Alissa covered exercise/tax liability with 1,445 shares, decreasing direct ownership by 1% to 115,532 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    1/5/26 6:00:03 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewis Darwin bought $20,651 worth of shares (3,955 units at $5.22), increasing direct ownership by 3% to 135,508 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/11/26 4:32:08 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $5,265 worth of shares (805 units at $6.54), increasing direct ownership by 0.62% to 131,553 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    12/17/25 4:23:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $4,882 worth of shares (450 units at $10.85), increasing direct ownership by 0.39% to 117,217 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    9/18/25 4:36:17 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products w

    2/4/26 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, today announced that after nine years at LifeVantage, Steve Fife, President, Chief Executive Officer and a member of the Board of Directors (the "Board"), has decided to retire in April, 2026. Fife will continue in his role as President and Chief Executive Officer during the transition period to ensure business continuity through his retirement date. The Board is conducting an extensive executive search and anticipates announcing the new CEO in the coming months. "To ensure continuity and po

    2/4/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the first quarter.Revenue in the Americas decreased 32.6%, and revenue in Asia/Pacific & Europe decreased 2.1%.Net income per diluted share was $0.02, versus $0.19 per diluted share a year ago;Adjusted earnings per diluted share was $0.15, compared

    2/4/26 4:04:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    SEC Filings

    View All

    SEC Form 10-Q filed by Lifevantage Corporation

    10-Q - Lifevantage Corp (0000849146) (Filer)

    2/4/26 4:05:35 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    2/4/26 4:06:04 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifevantage Corporation filed SEC Form 8-K: Leadership Update

    8-K - Lifevantage Corp (0000849146) (Filer)

    12/8/25 9:13:55 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation

    SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the addition of Mike Edwards as Chief Technology Officer. Edwards brings more than 25 years of experience as an accomplished senior executive specializing in technology leadership and enterprise transformation. "Mike is a strategic leader with a strong track record of translating technological innovation into measurable business impact and we are delighted to have him join the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "His expertise in eCo

    1/7/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer

    SALT LAKE CITY, Jan. 16, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is proud to announce the addition of Todd Thompson as Chief Information and Innovation Officer. Todd brings decades of experience driving transformative technology solutions and business growth for prominent global organizations. "We are thrilled to welcome Todd to the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "Todd's exceptional track record in technology leadership and his forward-thinking approach will be pivotal as we continue along our growth path

    1/16/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Financials

    Live finance-specific insights

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products w

    2/4/26 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the first quarter.Revenue in the Americas decreased 32.6%, and revenue in Asia/Pacific & Europe decreased 2.1%.Net income per diluted share was $0.02, versus $0.19 per diluted share a year ago;Adjusted earnings per diluted share was $0.15, compared

    2/4/26 4:04:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026

    SALT LAKE CITY, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its second quarter ended December 31, 2025, after the stock market closes on Wednesday, February 4, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hour

    1/21/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:29:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:27:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care